TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03274232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS ® 200
Description: micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
Study: NCT01914731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule
Study: NCT03334110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A method of operation: LIMA-GSV-SCVBG
Description: On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein

Intervention type: PROCEDURE
Group type: OTHER
Intervention: BIMA-SCVBG
Description: On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
Study: NCT00807131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient follow-up
Description: Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug dispensing
Description: The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pharmacy usual care
Description: The patient receives no information about their medicines in the pharmacy, unless he asks for it.
Study: NCT00605189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powered Suction Pump (VAC Freedom)
Description: continuous foam based negative pressure wound therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powered Suction Pump
Description: continuous gauze based negative pressure wound therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MWT
Description: moist wound therapy
Study: NCT03968406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03412708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation supported with Virtual Reality
Description: Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
Study: NCT03968406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT03412708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation supported with Virtual Reality
Description: Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
Study: NCT00657449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rofecoxib
Description: rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
Study: NCT00617851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lot A of Influenza virus vaccine
Description: 1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
Study: NCT03834844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
Study: NCT04265651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib 0.016 mg/kg
Description: Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib 0.032 mg/kg
Description: Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib 0.064 mg/kg
Description: Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth.
Study: NCT03834844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
Study: NCT04265651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib 0.128 mg/kg
Description: Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib 0.25 mg/kg
Description: Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth.
Study: NCT00617851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lot B of Influenza virus vaccine
Description: 1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lot C of Influenza virus vaccine
Description: 1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator influenza virus vaccine
Description: 1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: All 3 consecutive lots of influenza virus vaccine pooled
Description: 1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
Study: NCT00528827

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cardene® I.V.
Description: * 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardene® I.V.
Description: * 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardene® I.V.
Description: * 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V.
Study: NCT03834844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF Education
Description: 6 weekly education modules on topics related to AF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF Education
Description: 6 weekly education modules on topics related to AF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF Education
Description: 6 weekly education modules on topics related to AF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF Education
Description: 6 weekly education modules on topics related to AF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Weekly phone call to discuss patient concerns or questions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Weekly phone call to discuss patient concerns or questions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Weekly phone call to discuss patient concerns or questions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Weekly phone call to discuss patient concerns or questions
Study: NCT02861573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg
Description: Eight 50-mg capsules PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m^2
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: One 5-mg tablet PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: One 5-mg tablet PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg
Description: Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Description: Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg
Description: Two 150-mg tablets PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000 mg
Description: Two 500-mg or four 250-mg tablets PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg PO QD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab coformulation
Description: IV Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab coformulation
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV on Days 1, 2 and 3 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV on Days 1, 2 and 3 of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belzutifan 120mg
Description: PO QD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belzutifan 120mg
Description: PO QD
Study: NCT04716803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel Concentrated Platelet Rich Plasma (cPRP) System
Description: Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
Study: NCT01102361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Transperineal Biopsy
Description: Saturation biopsy for previous negative patients
Study: NCT01720719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Oral atorvastatin 20mg, qd, for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Oral Vitamin E 300mg, qd, for 24 weeks
Study: NCT04239339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Description: 20mg daily for approximately 3 weeks.
Study: NCT00528827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardene® I.V.
Description: * 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V.
Study: NCT04239339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for approximately 3 weeks.
Study: NCT00948337

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure of Secondary Cancer Screening
Description: One kind of printed educational material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure of Secondary Cancer Screening
Description: One kind of printed educational material
Study: NCT01561924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
Study: NCT02285348

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Description: Lumbar puncture is done according to general practice

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Description: Lumbar puncture is done according to general practice
Study: NCT02043314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazida
Study: NCT03473067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Norms Marketing Campaign
Description: This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capacity Building
Description: Schools will participate in teacher training and parent training.
Study: NCT01451320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: 3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptokinase
Description: 24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue plasminogen activator
Description: 5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: 6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: 6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
Study: NCT00810706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Patients randomised to receive exemestane (25 mg/day) for 5 years.
Study: NCT05467982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Illness Management and Recovery
Description: Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program
Description: Education and skills training groups on illness management of chronic conditions
Study: NCT02310503

Intervention type: PROCEDURE
Intervention: Mohs surgery
Description: A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
Study: NCT01921335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARRY-380 Twice Daily Dosage
Description: ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
Study: NCT02043314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazida
Study: NCT01257503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyland's Cold 'n Cough 4 kids
Description: 5 ml PO q4h prn cold symptoms
Study: NCT01921335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARRY-380 Once Daily
Description: ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6 mg/kg IV every 3 weeks
Study: NCT02402101

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: active tDCS
Description: Intensity 2 mA during 20 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Procedure: sham tDCS
Description: sham condition as delivered by the stimulator
Study: NCT01257503

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: liquid made to look like the active homeopathic remedy
Study: NCT01921335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6 mg/kg IV every 3 weeks
Study: NCT04238208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 5% patch
Description: 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine 5% patch
Description: 5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch, Per 10 Square Centimeters
Description: 8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
Study: NCT00890942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: naloxone 0.4mg.(1 ml) intramuscular

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 1 ml IM
Study: NCT03888521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resound Relief smartphone app
Description: The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
Study: NCT03105973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Enabled CBT Treatment
Description: CBT-based modules delivered via tablet over 4 weeks.
Study: NCT01362673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: Oral single 5 mg dose as one 5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: Oral single 10 mg dose as one 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: Oral single 30 mg dose as three 10 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral single dose as matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: Oral multiple 20 mg doses as two 10 mg tablets for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral multiple doses as matching placebo for 12 days
Study: NCT02123732

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DbXell

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01009515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, temozolomide
Description: Combination chemotherapy was administered for up to 6 cycles
Study: NCT02690051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeSmooth peripheral stent
Description: patients treated with the BeSmooth Peripheral Stent System
Study: NCT02180165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: 300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: 300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: 300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
Study: NCT03038763

Intervention type: OTHER
Intervention: Eligibility Screening
Description: Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.

Intervention type: DIAGNOSTIC_TEST
Intervention: HCV test
Description: Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.